Making the cut: untangling clinical protein biomarker discovery and validation.
暂无分享,去创建一个
[1] Sheri K. Wilcox,et al. Rapid Histochemistry Using Slow Off-rate Modified Aptamers With Anionic Competition , 2011, Applied immunohistochemistry & molecular morphology : AIMM.
[2] Joel N Hirschhorn,et al. Genome-wide association studies: results from the first few years and potential implications for clinical medicine. , 2011, Annual review of medicine.
[3] B. Kuster,et al. Proteomics: a pragmatic perspective , 2010, Nature Biotechnology.
[4] T. Jackson,et al. A Clathrin Independent Macropinocytosis-Like Entry Mechanism Used by Bluetongue Virus-1 during Infection of BHK Cells , 2010, PloS one.
[5] Tracy R. Keeney,et al. Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.
[6] Stephen A. Williams,et al. Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.
[7] F. Collins. Has the revolution arrived? , 2010, Nature.
[8] Dan Schneider,et al. Expanding the chemistry of DNA for in vitro selection. , 2010, Journal of the American Chemical Society.
[9] Alex Stewart,et al. Automation of the SomaLogic Proteomics Assay: A Platform for Biomarker Discovery , 2009 .
[10] D. Guyer,et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.
[11] Ruedi Aebersold,et al. Perspective: a program to improve protein biomarker discovery for cancer. , 2005, Journal of proteome research.
[12] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.